Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in Chinese Participants with Ulcerative Colitis
NCT05644665Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ozanimod in ulcerative colitis (UC), sponsored by Bristol Myers Squibb. Started Dec 2022; status: terminated.
02
Drugs
ozanimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05644665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644665.